Citations (119)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (28)
Doha Jbara, Maya Eiger-Moscovich, Elena Didkovsky, Yariv Keshet & Inbal Avisar. (2023) In Vivo Effects of Prostaglandin Analogues Application by Topical Drops or Retrobulbar Injections on the Orbital Fat of a Rat Model. Ocular Immunology and Inflammation 31:2, pages 298-303.
Read now
Read now
Adam P. Deveau, Flávia Nagel da Silva, Thai Yen Ly & Ahsen Hussain. (2023) Periocular invasive melanoma manifestation in a patient using bimatoprost: case report and literature review. Orbit 42:1, pages 73-80.
Read now
Read now
Andreas Katsanos, Ivano Riva, Banu Bozkurt, Gábor Holló, Luciano Quaranta, Francesco Oddone, Murat Irkec, Gordon N. Dutton & Anastasios G. Konstas. (2022) A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension. Expert Opinion on Drug Safety 21:4, pages 525-539.
Read now
Read now
Anastasios G. Konstas, Antoine Labbé, Andreas Katsanos, Frances Meier-Gibbons, Murat Irkec, Konstadinos G. Boboridis, Gábor Holló, Julián García-Feijoo, Gordon N. Dutton & Christophe Baudouin. (2021) The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. Expert Opinion on Drug Safety 20:4, pages 453-466.
Read now
Read now
Sarah MacIver, Nicole Stout & Olivia Ricci. (2021) New considerations for the clinical efficacy of old and new topical glaucoma medications. Clinical and Experimental Optometry 104:3, pages 350-366.
Read now
Read now
Viran Jayanetti, Sartaj Sandhu & Jed A Lusthaus. (2020) The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma. Journal of Experimental Pharmacology 12, pages 539-548.
Read now
Read now
Anastasios G. Konstas, Leopold Schmetterer, Vital P. Costa, Gábor Holló, Andreas Katsanos, Philippe Denis, Luciano Quaranta, Murat Irkec, Miguel A. Castejón, Miguel A. Teus & Alan L. Robin. (2020) Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review. Expert Opinion on Drug Safety 19:11, pages 1445-1460.
Read now
Read now
Khulood Muhammad Sayed, Engy Mohammed Mostafa, Amr Mounir, Nesreen G Abd Elhaliem & Alahmady Hamad Alsmman. (2019) Analysis of Bimatoprost-Induced changes on Rabbits eyelash Follicle: Clinical and Electron microscopic study. Clinical Ophthalmology 13, pages 2421-2426.
Read now
Read now
Andrea Angeli & Claudiu T Supuran. (2019) Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 – 2018). Expert Opinion on Therapeutic Patents 29:10, pages 793-803.
Read now
Read now
Sapir Karli, Juan Alfredo Ayala-Haedo, William J Feuer, Maria Fernandez, Sander Dubovy & Sara T Wester. (2018) Effect of prostaglandin analogs on matrix metalloproteinases and tissue inhibitor of metalloproteinases in eyelid muscle specimens. Clinical Ophthalmology 12, pages 2039-2046.
Read now
Read now
Anastasios G. P. Konstas & Gabor Holló. (2016) Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma. Expert Opinion on Pharmacotherapy 17:9, pages 1271-1283.
Read now
Read now
Yuan Fang, Zhihong Ling & Xinghuai Sun. (2015) Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol. Drug Design, Development and Therapy 9, pages 2617-2625.
Read now
Read now
Gábor Holló & Andreas Katsanos. (2015) Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. Expert Opinion on Drug Safety 14:4, pages 609-617.
Read now
Read now
Katsuhiko Maruyama, Asako Tsuchisaka, Jumpei Sakamoto, Shiroaki Shirato & Hiroshi Goto. (2013) Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patients. Clinical Ophthalmology 7, pages 1441-1446.
Read now
Read now
Nathan V Harms & Carol B Toris. (2013) Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease. Expert Opinion on Pharmacotherapy 14:1, pages 105-113.
Read now
Read now
Donald R Nixon, Susan Simonyi, Meetu Bhogal, Christopher S Sigouin, Andrew C Crichton, Marino Discepola, Cindy ML Hutnik & David B Yan. (2012) An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial. Clinical Ophthalmology 6, pages 2097-2103.
Read now
Read now
Maurizio Digiuni, Paolo Fogagnolo & Luca Rossetti. (2012) A review of the use of latanoprost for glaucoma since its launch. Expert Opinion on Pharmacotherapy 13:5, pages 723-745.
Read now
Read now
Pertti Pellinen, Anne Huhtala, Ari Tolonen, Jukka Lokkila, Jukka Mäenpää & Hannu Uusitalo. (2012) The Cytotoxic Effects of Preserved and Preservative-Free Prostaglandin Analogs on Human Corneal and Conjunctival Epithelium In Vitro and the Distribution of Benzalkonium Chloride Homologs in Ocular Surface Tissues In Vivo. Current Eye Research 37:2, pages 145-154.
Read now
Read now
David Wirta, Amanda M VanDenburgh, Emily Weng, Scott M Whitcup, Sef Kurstjens & Frederick C Beddingfield$suffix/text()$suffix/text(). (2011) Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials. Clinical Ophthalmology 5, pages 759-765.
Read now
Read now
Marina Papadia, Alessandro Bagnis, Riccardo Scotto & Carlo E Traverso. (2011) Tafluprost for glaucoma. Expert Opinion on Pharmacotherapy 12:15, pages 2393-2401.
Read now
Read now
Steven Fagien. (2010) Management of hypotrichosis of the eyelashes: Focus on bimatoprost. Clinical, Cosmetic and Investigational Dermatology 3, pages 39-48.
Read now
Read now
E Randy Craven, Ching-Chi Liu, Amy Batoosingh, Rhett M Schiffman & Scott M Whitcup. (2010) A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost. Clinical Ophthalmology 4, pages 1433-1440.
Read now
Read now
Dietmar Schnober, Günter Hofmann, Hubert Maier, Maria-Luise Scherzer, Abayomi B Ogundele & Mark C Jasek. (2010) Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clinical Ophthalmology 4, pages 1459-1463.
Read now
Read now
Anuradha Jayaprakasam & Seyed Ghazi-Nouri. (2010) Periorbital Fat Atrophy — An Unfamiliar Side Effect of Prostaglandin Analogues. Orbit 29:6, pages 357-359.
Read now
Read now
Sayime Aydin, Işıl Işıklıgil, Yasemin Aktan Tekşen & Erkin Kir. (2010) Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature. Cutaneous and Ocular Toxicology 29:3, pages 212-216.
Read now
Read now
Oghenowede Eyawo, Jean Nachega, Pierre Lefebvre, David Meyer, Beth Rachlis, Chia-Wen Lee, Steven Kelly & Edward Mills. (2009) Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clinical Ophthalmology 3, pages 447-456.
Read now
Read now
Ciro Costagliola, Roberto dell’Omo, Mario R Romano, Michele Rinaldi, Lucia Zeppa & Francesco Parmeggiani. (2009) Pharmacotherapy of intraocular pressure – part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opinion on Pharmacotherapy 10:17, pages 2859-2870.
Read now
Read now
Philippe Denis, David Covert & Anthony Realini. (2007) Travoprost in the management of open-angle glaucoma and ocular hypertension. Clinical Ophthalmology 1:1, pages 11-24.
Read now
Read now
Articles from other publishers (91)
Anne Hedengran, Josefine Freiberg, Pernille May Hansen, Gerard Boix-Lemonche, Tor P. Utheim, Darlene A. Dartt, Goran Petrovski, Steffen Heegaard & Miriam Kolko. (2024) Comparing the effect of benzalkonium chloride-preserved, polyquad-preserved, and preservative-free prostaglandin analogue eye drops on cultured human conjunctival goblet cells. Journal of Optometry 17:1, pages 100481.
Crossref
Crossref
Nathan M. Radcliffe, Manjool Shah & Thomas W. Samuelson. (2023) Challenging the "Topical Medications-First” Approach to Glaucoma: A Treatment Paradigm in Evolution. Ophthalmology and Therapy 12:6, pages 2823-2839.
Crossref
Crossref
Laure Chauchat, Camille Guerin, Yulia Kaluzhny & Jean-Paul Renard. (2023) Comparison of In Vitro Corneal Permeation and In Vivo Ocular Bioavailability in Rabbits of Three Marketed Latanoprost Formulations. European Journal of Drug Metabolism and Pharmacokinetics 48:6, pages 633-645.
Crossref
Crossref
Hyun Woo Kim, Chong Eun Lee, Sam Seo, Kyoo Won Lee & Chang Hoon Lee. (2023) Latanoprostene Bunod 0.024% w/v Treatment of Open-anlge Glaucoma: Short-term Effects, Safety, and Changes in Ocular Blood. Journal of the Korean Ophthalmological Society 64:10, pages 930-938.
Crossref
Crossref
Kevin Y. Wu, Jamie K. Fujioka, Tara Gholamian, Marian Zaharia & Simon D. Tran. (2023) Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery. Pharmaceuticals 16:9, pages 1241.
Crossref
Crossref
Jose Manuel Abalo-Lojo, Pedro Vázquez Ferreiro, Maria Knight Asorey, Aida Estévez Colmenero & Francisco Gonzalez. (2023) Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment. Turkish Journal of Ophthalmology 53:1, pages 8-12.
Crossref
Crossref
Emily L. Meany, Roxanne Andaya, Shijia Tang, Catherine M. Kasse, Reina N. Fuji, Abigail K. Grosskopf, Andrea L. d'Aquino, Joshua T. Bartoe, Ryan Ybarra, Amy Shelton, Zachary Pederson, Chloe Hu, Dennis Leung, Karthik Nagapudi, Savita Ubhayakar, Matthew Wright, Chun‐Wan Yen & Eric A. Appel. (2022) Injectable Polymer‐Nanoparticle Hydrogel for the Sustained Intravitreal Delivery of Bimatoprost. Advanced Therapeutics 6:2.
Crossref
Crossref
Masashi Kumon, Masahiro Fuwa, Atsushi Shimazaki, Noriko Odani-Kawabata, Ryo Iwamura, Kenji Yoneda & Masatomo Kato. (2023) Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells. PLOS ONE 18:1, pages e0280331.
Crossref
Crossref
Giulia Coco, Danilo Iannetta, Igino Febbraro, Ester Elmo & Gianluca Manni. (2022) Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study. Journal of Ophthalmology 2022, pages 1-8.
Crossref
Crossref
Balini Balasubramaniam, Yu Jeat Chong, Matthew Azzopardi, Abison Logeswaran & Alastair K Denniston. (2022) Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives. Journal of Inflammation Research Volume 15, pages 6439-6451.
Crossref
Crossref
Nilgün Yıldırım, Banu Bozkurt, Nurşen Yüksel, Halil Ateş, Rana Altan-Yaycıoğlu, Özcan Ocakoğlu, Ayşe Burcu, Ilgaz Yalvaç, Özlem Evren Kemer & Mehmet Orhan. (2022) Prevalence of Ocular Surface Disease and Associated Risk Factors in Glaucoma Patients: A Survey Study of Ophthalmologists. Turkish Journal of Ophthalmology 52:5, pages 302-308.
Crossref
Crossref
Lin Zhou, Wenyi Zhan & Xin Wei. (2022) Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Frontiers in Pharmacology 13.
Crossref
Crossref
Jong-Wook Lee, Hyeon-Soo Ahn, Jinho Chang, Hye-Young Kang, Dong-Jin Chang, Jae Kyung Suh & Hankil Lee. (2022) Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. Korean Journal of Ophthalmology 36:5, pages 423-434.
Crossref
Crossref
Jeong Yeub Kim & Jae Woo Kim. (2022) Effect of Prostaglandin E2 Agonist Omidenepag on the Expression of Matrix Metalloproteinase in Trabecular Meshwork Cells. Korean Journal of Ophthalmology 36:2, pages 123-130.
Crossref
Crossref
Songjia Tang, Xiaoxin Wu, Peihua Liu, Jinsheng Li, Chunmao Han & Jufang Zhang. (2021) Modified single‐hair follicular unit grafting to esthetically restore eyelashes in Asians. Journal of Cosmetic Dermatology 21:3, pages 1106-1110.
Crossref
Crossref
Yushun Xue, Quancai Gao & Ling Zhang. (2022) Extended ocular delivery of latanoprost from niosome-laden contact lenses: In vitro characterization and in vivo studies. Journal of Drug Delivery Science and Technology 68, pages 103044.
Crossref
Crossref
Jessica Sze Chia Ng, Yi Xin Tan, Nor Amalina Ahmad Alwi, Kar Ming Yee, Ahmad Hazri Abdul Rashid, Ka-Liong Tan & Chuei Wuei Leong. (2022) In Vitro Toxicity Evaluation of New Generic Latanost® and Latacom® as an Ophthalmic Formulation. Journal of Current Glaucoma Practice 15:3, pages 139-143.
Crossref
Crossref
Jillian F. Ziemanski, Landon WilsonStephen BarnesKelly K. Nichols. (2022) Prostaglandin E2 and F2α Alter Expression of Select Cholesteryl Esters and Triacylglycerols Produced by Human Meibomian Gland Epithelial Cells. Cornea 41:1, pages 95-105.
Crossref
Crossref
Sapna Sinha, Wesam Shamseldin Shalaby, Wendy W. Liu, Reza Razeghinejad & L. Jay Katz. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
612
661
.
Masahiro FuwaAtsushi ShimazakiNoriko Odani-KawabataTomoko KiriharaTakazumi TaniguchiRyo IwamuraKenji YonedaMasatomo KatoKenji MorishimaNaveed K. Shams. (2021) Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys. Journal of Ocular Pharmacology and Therapeutics 37:4, pages 223-229.
Crossref
Crossref
Su Min Sung, Jong Heon Kim, Chong Eun Lee, Kyoo Won Lee & Sam Seo. (2021) Effect and Safety of Travoprost 0.003% in Open Angle Glaucoma. Journal of the Korean Ophthalmological Society 62:4, pages 531-537.
Crossref
Crossref
Najam A. Sharif. (2020) Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810. ACS Pharmacology & Translational Science 3:6, pages 1391-1421.
Crossref
Crossref
Yue Guo, Jun Young Ha, He Long Piao, Mi Sun Sung & Sang Woo Park. (2020) The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study. BMC Ophthalmology 20:1.
Crossref
Crossref
Yoshihiko EsakiOsamu KatsutaHitomi KamioTakahisa NotoHidetoshi ManoRyo IwamuraKenji YonedaNoriko Odani-KawabataKenji MorishimaNaveed K. Shams. (2020) The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice. Journal of Ocular Pharmacology and Therapeutics 36:7, pages 529-533.
Crossref
Crossref
Makoto Aihara, Auli Ropo, Fenghe Lu, Hisashi Kawata, Akihiro Iwata, Noriko Odani-Kawabata & Naveed Shams. (2020) Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study. Japanese Journal of Ophthalmology 64:4, pages 398-406.
Crossref
Crossref
Lipi Chakrabarty. (2020) Systemic side effects of topical prostaglandin analogues: Rare but real. Indian Journal of Ophthalmology 68:11, pages 2637.
Crossref
Crossref
Marcelo Luís Occhiutto, Raul C. Maranhão, Vital Paulino Costa & Anastasios G. Konstas. (2019) Nanotechnology for Medical and Surgical Glaucoma Therapy—A Review. Advances in Therapy 37:1, pages 155-199.
Crossref
Crossref
Wencui Shen, Bingqing Huang & Jin Yang. (2019) Ocular Surface Changes in Prostaglandin Analogue-Treated Patients. Journal of Ophthalmology 2019, pages 1-7.
Crossref
Crossref
Letizia Negri, Antonio Ferreras & Michele Iester. (2019) Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life. Journal of Ophthalmology 2019, pages 1-12.
Crossref
Crossref
Jennifer R. SealMichael R. RobinsonJames BurkeMarina BejanianMichael CooteMayssa Attar. (2019) Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues. Journal of Ocular Pharmacology and Therapeutics 35:1, pages 50-57.
Crossref
Crossref
S. Lazreg, Z. Merad, M.T. Nouri, R. Garout, A. Derdour, N. Ghroud, R. Kherroubi, M. Meziane, S. Belkacem, O. Ouhadj, C. Baudouin & M. Tiar. (2018) Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications. Journal Français d'Ophtalmologie 41:10, pages 945-954.
Crossref
Crossref
Jie Shen, Guang Wei Lu & Patrick Hughes. (2018) Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations. Pharmaceutical Research 35:11.
Crossref
Crossref
Masahiro FuwaCarol B. TorisShan FanTakazumi TaniguchiMasaki IchikawaNoriko Odani-KawabataRyo IwamuraKenji YonedaTakeshi MatsugiNaveed K. ShamsJin-Zhong Zhang. (2018) Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. Journal of Ocular Pharmacology and Therapeutics 34:7, pages 531-537.
Crossref
Crossref
Laura M. Dutca, Danielle Rudd, Victor Robles, Anat Galor, Mona K. Garvin & Michael G. Anderson. (2018) Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice. Scientific Reports 8:1.
Crossref
Crossref
Janika Nättinen, Antti Jylhä, Ulla Aapola, Minna Parkkari, Alexandra Mikhailova, Roger W. Beuerman & Hannu Uusitalo. (2018) Patient stratification in clinical glaucoma trials using the individual tear proteome. Scientific Reports 8:1.
Crossref
Crossref
Yiran Yang, Caihong Huang, Xiang Lin, Yang Wu, Weijie Ouyang, Liying Tang, Sihao Ye, Yuhong Wang, Wei Li, Xiaobo Zhang & Zuguo Liu. (2018) 0.005% Preservative-Free Latanoprost Induces Dry Eye-Like Ocular Surface Damage via Promotion of Inflammation in Mice. Investigative Opthalmology & Visual Science 59:8, pages 3375.
Crossref
Crossref
R Mancino, E Di Carlo, D Napoli, A Martucci, A Mauro, Sorge RP, M Cesareo & C Nucci. (2018) Anterior Segment Optical Coherence Tomography Analysis of Iris Morphometric Changes Induced by Prostaglandin Analogues Treatment in Patients with Primary Open Angle Glaucoma or Ocular Hypertension. The Open Ophthalmology Journal 12:1, pages 110-120.
Crossref
Crossref
V. P. Erichev & V. S. Zinina. (2018) Latanoprost in hypotensive therapy of glaucoma. Vestnik oftal'mologii 134:4, pages 91.
Crossref
Crossref
Gábor Holló, Andreas Katsanos, Kostas G. Boboridis, Murat Irkec & Anastasios G. P. Konstas. (2017) Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. Drugs 78:1, pages 39-64.
Crossref
Crossref
Orsolya N Horváth, Valerie Letulé, Thomas Ruzicka, Thomas Herzinger, Ilana Goldscheider & Tanja von Braunmühl. (2017) Periocular discoloration after using a prostaglandin analog for eyelash enhancement: evaluation with reflectance confocal microscopy. Journal of Cosmetic Dermatology 16:1, pages 18-20.
Crossref
Crossref
Richard A. Lewis, William C. Christie, Douglas G. Day, E. Randy Craven, Thomas Walters, Marina Bejanian, Susan S. Lee, Margot L. Goodkin, Jane Zhang, Scott M. Whitcup, Michael R. Robinson, Tin Aung, Allen D. Beck, William C. Christie, Michael Coote, Charles J. Crane, E. Randy Craven, Andrew Crichton, Douglas G. Day, F. Jane Durcan, William J. Flynn, Sébastien Gagné, Damien F. Goldberg, Delan Jinapriya, C. Starck Johnson, Shimon Kurtz, Richard A. Lewis, Steven L. Mansberger, Shamira A. Perera, Michael H. Rotberg, Robert M. Saltzmann, Howard I. Schenker, Michael E. Tepedino, Maria Imelda R. Yap-Veloso, Harvey S. Uy & Thomas R. Walters. (2017) Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial. American Journal of Ophthalmology 175, pages 137-147.
Crossref
Crossref
. (2017) Factors Related to Prostaglandin-Associated Periorbitopathy in Glaucoma Patients. Asia-Pacific Journal of Ophthalmology.
Crossref
Crossref
Yoshihiko Esaki, Atsushi Shimazaki & Pertti Pellinen. (2016) Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study. The Open Ophthalmology Journal 10:1, pages 146-153.
Crossref
Crossref
Emilia Marchei, Daniela De Orsi, Carmine Guarino, Maria Rotolo, Silvia Graziano & Simona Pichini. (2016) High Performance Liquid Chromatography Tandem Mass Spectrometry Measurement of Bimatoprost, Latanoprost and Travoprost in Eyelash Enhancing Cosmetic Serums. Cosmetics 3:1, pages 4.
Crossref
Crossref
Gábor Holló & Péter Kóthy. (2015) Prostaglandin Analogue–Induced Pigmentation of the Skin of the Nasal Septum and Nasal Alae in a Glaucoma Patient. European Journal of Ophthalmology 25:4, pages e38-e39.
Crossref
Crossref
I. Rodríguez Uña, J.M. Martínez-de-la-Casa, L. Pablo Júlvez, J.A. Martínez Compadre, J. García Feijoo, J.I. Belda Sanchís, M.I. Canut Jordana, J. Hernández-Barahona Palma, F.J. Muñoz Negrete & J.L. Urcelay Segura. (2015) Perioperative pharmacological management in patients with glaucoma. Archivos de la Sociedad Española de Oftalmología (English Edition) 90:6, pages 274-284.
Crossref
Crossref
I. Rodríguez Uña, J.M. Martínez-de-la-Casa, L. Pablo Júlvez, J.A. Martínez Compadre, J. García Feijoo, J.I. Belda Sanchís, M.I. Canut Jordana, J. Hernández-Barahona Palma, F.J. Muñoz Negrete & J.L. Urcelay Segura. (2015) Manejo farmacológico perioperatorio en pacientes con glaucoma. Archivos de la Sociedad Española de Oftalmología 90:6, pages 274-284.
Crossref
Crossref
Steven Fagien. (2015) Management of Hypotrichosis of the Eyelashes. Plastic Surgical Nursing 35:2, pages 82-91.
Crossref
Crossref
E. Santos-Bueso, F. Sáenz-Francés, L. Palmero-Fernández, S. García-Sáenz, J.M. Martínez-de-la-Casa, J. García-Feijoo & J. García-Sánchez. (2015) Hypertension secondary to treatment with latanoprost. Archivos de la Sociedad Española de Oftalmología (English Edition) 90:1, pages 37-39.
Crossref
Crossref
E. Santos-Bueso, F. Sáenz-Francés, L. Palmero-Fernández, S. García-Sáenz, J.M. Martínez-de-la-Casa, J. García-Feijoo & J. García-Sánchez. (2015) Hipertensión arterial secundaria a tratamiento con latanoprost. Archivos de la Sociedad Española de Oftalmología 90:1, pages 37-39.
Crossref
Crossref
Denise Goodwin & Dina H. Erickson. (2014) Accidental Overdose of Travoprost. Optometry and Vision Science 91:12, pages e298-e300.
Crossref
Crossref
Y. K. Lee, J. Y. Lee, J. I. Moon & M. H. Park. (2014) Effectiveness of the ICare rebound tonometer in patients with overestimated intraocular pressure due to tight orbit syndrome. Japanese Journal of Ophthalmology 58:6, pages 496-502.
Crossref
Crossref
James B. Wittenberg, Wanlong Zhou, Perry G. Wang & Alexander J. Krynitsky. (2014) Determination of prostaglandin analogs in cosmetic products by high performance liquid chromatography with tandem mass spectrometry. Journal of Chromatography A 1359, pages 140-146.
Crossref
Crossref
Gábor Holló, Jouni Vuorinen, Juhani Tuominen, Teppo Huttunen, Auli Ropo & Norbert Pfeiffer. (2014) Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products. Advances in Therapy 31:9, pages 932-944.
Crossref
Crossref
M Figus, M Nardi, P Piaggi, M Sartini, G Guidi, L Martini & S Lazzeri. (2014) Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients. Eye 28:4, pages 422-429.
Crossref
Crossref
K. Harii, S. Arase, R. Tsuboi, E. Weng, S. Daniels & A. VanDenburgh. (2014) Bimatoprost for Eyelash Growth in Japanese Subjects: Two Multicenter Controlled Studies. Aesthetic Plastic Surgery 38:2, pages 451-460.
Crossref
Crossref
Katsuhiko Maruyama, Shiroaki Shirato & Asako Tsuchisaka. (2014) Incidence of Deepening of the Upper Eyelid Sulcus After Topical Use of Travoprost Ophthalmic Solution in Japanese. Journal of Glaucoma 23:3, pages 160-163.
Crossref
Crossref
Michel Cucherat, Ingeborg Stalmans & Jean-François Rouland. (2014) Relative Efficacy and Safety of Preservative-free Latanoprost (T2345) for the Treatment of Open-Angle Glaucoma and Ocular Hypertension. Journal of Glaucoma 23:1, pages e69-e75.
Crossref
Crossref
Ivano Riva, Andreas Katsanos, Irene Floriani, Elena Biagioli, Anastasios G.P. Konstas, Marco Centofanti & Luciano Quaranta. (2014) Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma. Journal of Glaucoma 23:8, pages 535-540.
Crossref
Crossref
Amália Turner GiannicoLeandro LimaHeloisa Helena Abil RussFabiano Montiani-Ferreira. (2013) Eyelash Growth Induced by Topical Prostaglandin Analogues, Bimatoprost, Tafluprost, Travoprost, and Latanoprost in Rabbits. Journal of Ocular Pharmacology and Therapeutics 29:9, pages 817-820.
Crossref
Crossref
Douglas G Day, Thomas R Walters, Gail F Schwartz, Thomas K Mundorf, Charlie Liu, Rhett M Schiffman & Marina Bejanian. (2013) Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. British Journal of Ophthalmology 97:8, pages 989-993.
Crossref
Crossref
Iwona Dams, Jaromir Wasyluk, Marek Prost & Andrzej Kutner. (2013) Therapeutic uses of prostaglandin F2α analogues in ocular disease and novel synthetic strategies. Prostaglandins & Other Lipid Mediators 104-105, pages 109-121.
Crossref
Crossref
Andrew C. S. Crichton, Steven Vold, Julia M. Williams & David A. Hollander. (2013) Ocular Surface Tolerability of Prostaglandin Analogs and Prostamides in Patients with Glaucoma or Ocular Hypertension. Advances in Therapy 30:3, pages 260-270.
Crossref
Crossref
Martina Tomić, Snježana Kaštelan, Kata Metež Soldo & Jasminka Salopek-Rabatić. (2013) Influence of BAK-Preserved Prostaglandin Analog Treatment on the Ocular Surface Health in Patients with Newly Diagnosed Primary Open-Angle Glaucoma. BioMed Research International 2013, pages 1-7.
Crossref
Crossref
Suping Cai, Xiaomin Zhou, Naihong Yan, Xuyang Liu & Xiaohong Li. (2013) Possible mechanism for the gastro-intestinal adverse effects upon topical application of Prostaglandin F2α analogs. Medical Hypotheses 80:1, pages 32-35.
Crossref
Crossref
Jongwoo Shim, Changhun Park, Hyun Soo Lee, Min Soo Park, Hyung Taek Lim, Sunil Chauhan, Reza Dana, Hyon Lee & Hyung Keun Lee. (2012) Change in Prostaglandin Expression Levels and Synthesizing Activities in Dry Eye Disease. Ophthalmology 119:11, pages 2211-2219.
Crossref
Crossref
Mano Sira, David Harding Verity & Raman Malhotra. (2012) Topical Bimatoprost 0.03% and Iatrogenic Eyelid and Orbital Lipodystrophy. Aesthetic Surgery Journal 32:7, pages 822-824.
Crossref
Crossref
Hee Young ChoiJi Eun LeeJi Woong LeeHyun Jun ParkJi Eun LeeJae Ho Jung. (2012)
In Vitro
Study of Antiadipogenic Profile of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in Human Orbital Preadiopocytes
. Journal of Ocular Pharmacology and Therapeutics 28:2, pages 146-152.
Crossref
Crossref
Esra Ayhan Tuzcu, Ugurcan Keskin, Mesut Coskun, Ozgur Ilhan, Mutlu Daglıoglu & Huseyin Oksuz. (2012) Bilateral Serous Detachment Associated with Latanoprost/Timolol Fixed Combination Use: A Report of One Phakic Case. Case Reports in Ophthalmological Medicine 2012, pages 1-3.
Crossref
Crossref
Makoto Aihara, Shiroaki Shirato & Rei Sakata. (2011) Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Japanese Journal of Ophthalmology 55:6, pages 600-604.
Crossref
Crossref
Alessandro Bagnis, Marina Papadia, Riccardo Scotto & Carlo E. Traverso. (2011) Antiglaucoma drugs: The role of preservative-free formulations. Saudi Journal of Ophthalmology 25:4, pages 389-394.
Crossref
Crossref
Maria-Luise Scherzer, Ivana Liehneova, Francisco Jose Muñoz Negrete & Dietmar Schnober. (2011) Travoprost 0.004%/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03%/timolol 0.5%. Advances in Therapy 28:8, pages 661-670.
Crossref
Crossref
Derek Jones. (2010) Enhanced Eyelashes: Prescription and Over-the-Counter Options. Aesthetic Plastic Surgery 35:1, pages 116-121.
Crossref
Crossref
JOEL L. COHEN. (2010) Enhancing the Growth of Natural Eyelashes: The Mechanism of Bimatoprost-Induced Eyelash Growth. Dermatologic Surgery 36:9, pages 1361-1371.
Crossref
Crossref
Paul Palmberg, Elizabeth E. Kim, Kenneth K. Kwok & Charles S. Tressler. (2018) A 12-Week, Randomized, Double-Masked Study of Fixed Combination Latanoprost/Timolol versus Latanoprost or Timolol Monotherapy. European Journal of Ophthalmology 20:4, pages 708-718.
Crossref
Crossref
Jess T. WhitsonWilliam B. TrattlerCynthia MatossianJulia WilliamsDavid A. Hollander. (2010) Ocular Surface Tolerability of Prostaglandin Analogs in Patients with Glaucoma or Ocular Hypertension. Journal of Ocular Pharmacology and Therapeutics 26:3, pages 287-292.
Crossref
Crossref
L. Jay Katz, John S. Cohen, Amy L. Batoosingh, Carlos Felix, Vincent Shu & Rhett M. Schiffman. (2010) Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension. American Journal of Ophthalmology 149:4, pages 661-671.e1.
Crossref
Crossref
Vivek Gupta, Amit Rawat & Fakhrul Ahsan. (2010) Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension. Journal of Pharmaceutical Sciences 99:4, pages 1774-1789.
Crossref
Crossref
Donald J. AbrahamKlimko Peter Gerard. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
569
618
.
Marc R. Avram & Nicole E. RogersAlan J. Bauman. 2010. Hair Transplantation. Hair Transplantation
73
84
.
Kathryn P.B. Cracknell & Ian Grierson. (2009) Prostaglandin analogues in the anterior eye: Their pressure lowering action and side effects. Experimental Eye Research 88:4, pages 786-791.
Crossref
Crossref
Kazutaka Kamiya & Kimiya Shimizu. (2009) Reply. American Journal of Ophthalmology 147:4, pages 754-755.
Crossref
Crossref
Albert Alm, Ian Grierson & M. Bruce Shields. (2008) Side Effects Associated with Prostaglandin Analog Therapy. Survey of Ophthalmology 53:6, pages S93-S105.
Crossref
Crossref
Jean François Michelet, Laurent Colombe, Brigitte Gautier, Olivier Gaillard, Florence Benech, Rui Pereira, Christophe Boulle, Maria Dalko-Csiba, Roger Rozot, Michel Neuwels & Bruno Alain Bernard. (2008)
Expression of NAD
+
dependent 15-hydroxyprostaglandin dehydrogenase and protection of prostaglandins in human hair follicle
. Experimental Dermatology 17:10, pages 821-828.
Crossref
Crossref
Sriram SontyVikrant DonthamsettiGautam VangipuramAfzal Ahmad. (2008) Long-Term IOP Lowering With Bimatoprost in Open-Angle Glaucoma Patients Poorly Responsive to Latanoprost. Journal of Ocular Pharmacology and Therapeutics 24:5, pages 517-520.
Crossref
Crossref
D.F. Woodward, R.W.C. Carling, C.L. Cornell, H.G. Fliri, J.L. Martos, S.N. Pettit, Y. Liang & J.W. Wang. (2008) The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacology & Therapeutics 120:1, pages 71-80.
Crossref
Crossref
Tsutomu Ishihara, Miyuki Takahashi, Megumu Higaki, Mitsuko Takenaga, Tohru Mizushima & Yutaka Mizushima. (2008) Prolonging the In Vivo Residence Time of Prostaglandin E1 with Biodegradable Nanoparticles. Pharmaceutical Research 25:7, pages 1686-1695.
Crossref
Crossref
D F Woodward, Y Liang & A H-P Krauss. (2008) Prostamides (prostaglandin-ethanolamides) and their pharmacology. British Journal of Pharmacology 153:3, pages 410-419.
Crossref
Crossref
Stéphanie Payet, Philippe Denis, Gilles Berdeaux & Robert Launois. (2008) Assessment of the Cost Effectiveness of Travoprost versus Latanoprost as Single Agents for Treatment of Glaucoma in France. Clinical Drug Investigation 28:3, pages 183-198.
Crossref
Crossref
W.C. Stewart, J.A. Stewart, L.A. Nelson & B. Kruft. (2018) Physician Attitudes regarding Prostaglandin Treatment for Glaucoma in the United States and Europe. European Journal of Ophthalmology 18:2, pages 199-204.
Crossref
Crossref
Sayime Aydın & Fatih Özcura. (2007) Corneal oedema and acute anterior uveitis after two doses of travoprost. Acta Ophthalmologica Scandinavica 85:6, pages 693-694.
Crossref
Crossref